Ziva DRA supports pharmaceutical companies with regulatory assessment, source documentation review, compliance preparation and coordination of API source validation requirements for the Bangladesh market.
An API source is a critical component of a pharmaceutical product's regulatory and quality profile. Introducing or changing a source should therefore be assessed in the context of the finished medicine, available technical information and current regulatory requirements.
Ziva DRA helps pharmaceutical companies review the proposed API source, identify relevant documentation, assess regulatory readiness and coordinate the source-validation workstream.
API source validation can also be connected with medicine registration, dossier preparation, GMP consulting and broader pharmaceutical regulatory support where required.
The exact scope should be defined against the specific API, pharmaceutical product and current regulatory requirements.
Review the proposed API manufacturer, source profile and relevant regulatory context.
Assess the likely regulatory requirements associated with the API source.
Evaluate available source, quality, manufacturer and supporting regulatory records.
Assess source-related technical information relevant to the regulatory file.
Organize information and documentation required for the applicable validation process.
Support relevant future source changes or continuing regulatory requirements.
The regulatory route can vary, but the project can be managed through a clear source-review-to-compliance workflow.
Review proposed manufacturer and API source details.
Identify likely regulatory and documentation requirements.
Review and organize source-related records.
Coordinate applicable regulatory preparation and follow-up.
Support relevant ongoing source obligations.
Required information depends on the API, manufacturer, finished pharmaceutical product and current regulatory pathway.
A clear source and manufacturer profile provides the foundation for the regulatory assessment.
Supporting information should be assessed against the current regulatory requirement for the specific source-validation project.
Finished-product manufacturers adding or changing an API source.
API manufacturers supporting customers with Bangladesh regulatory requirements.
Overseas companies requiring local regulatory and documentation coordination.
Regulatory teams managing source changes or pharmaceutical registration projects.
Yes. The proposed source can first be reviewed against the pharmaceutical product, manufacturer information and applicable regulatory requirements.
Yes. An initial regulatory and documentation review can help identify gaps before defining the final scope.
Not necessarily. Requirements can depend on the finished product, proposed source and current regulatory pathway.
Yes. Where relevant, medicine registration, dossier preparation and API source validation can be coordinated within one broader regulatory project.
Share the API, manufacturer, finished-product context and available supporting documentation with Ziva DRA so the relevant regulatory pathway and project scope can be assessed.